Dry cultural virus vaccine against plague in small ruminant animals

FIELD: veterinary science, infectious diseases.

SUBSTANCE: invention relates to the development of dry cultural virus vaccine against plague in small ruminant animals that possesses high immunogenicity, harmlessness, areactogenic properties for sheep and goats and low cost. Virus vaccine comprises lyophilized virus-containing material prepared on base of the strain "45G37/35-K" and protective medium in the volume ratio 1:1. As protective medium virus vaccine comprises medium of the following composition, wt.-%: enzymatic peptone, 9.8-10.2; lactose, 1.8-2.2, and distilled water, the balance. Vaccine is harmless, shows highly immunogenic properties and stable in storage.

EFFECT: improved and valuable properties of vaccine.

2 cl, 3 ex

 

The invention relates to the field of veterinary medicine, namely to develop VirusWall designed for the specific prophylaxis of plague of small ruminants.

In disadvantaged by the plague of small ruminants countries for prevention of specific diseases apply VirusWall derived from attenuated strains of viruses plague of small ruminants (CMGI) and rinderpest (CCRS), which have antigenic relatedness and genetic similarity[4, 7, 8, 9, 10].

There are also reports on the development of inactivated and recombinant vaccines, which, however, are not widely used in veterinary practice [1, 2].

Heterologous vaccine-derived vaccine virus CCRS protect sheep and goats from clinical manifestations CMGI, but do not prevent reproduction in the organism virulent virus. In this regard, the authors do not recommend the use of such drugs for vaccination of small ruminants [3, 6].

For prevention of specific diseases in disadvantaged areas are widely used VirusWall, which is obtained on the basis of the attenuated strain of "Nigeria 75/1 virus CMGI and its variants[2, 5, 10].

Unfavorable epizootic situation on CMGI in 1990-2003 GGA the territory of several countries (India, Turkey, Iran, Iraq, Israel, and others), having the trade is conomic relations with Russia, and the lack of a vaccine against this disease pointed to the need to develop means of specific prophylaxis against plague of small ruminants.

Closest to the proposed invention (prototype) is virusvaktsinu from strain 75/1 LK6 BK2 Vero70", creating a tight immunity in animals 21 days after vaccination with a duration of more than one year [10]. However, the disadvantage of this VirusWall is that the vaccine virus is grown in human cell culture VERO, which is grown on a nutrient medium Needle MEM with fetal calf serum with a high cost.

The aim of the invention is a dry cultural virusvaktsinu against the plague of small ruminants with high immunogenicity, safety, reactogenicity for sheep and goats, and low cost.

This goal is achieved using when designing VirusWall new vaccine strain "45G37/35-virus CMGI grown in primary culture cells of the kidneys or testicles lamb on a nutrient medium for the cultivation of the Needle MEM or CHAP with serum Cree used instead of fetal calf serum, which is not produced in Russia and CIS countries, it significantly reduces the cost of the vaccine.

Vaccinal strain bred by passirovannym of attenborrow the aqueous strain "45g", in primary cultures of kidney cells and lamb testicles and transplantable - kidney saiga. Strain harmless and reactogenic for sheep and goats, has high immunogenicity and accumulates in these cell cultures in the titer of 5.0-6.0 lg TCD50/cm3. The specified strain deposited 14.12.04, as production in the Public collections of strains of microorganisms UHF all-Russian state centre for quality and standardization of drugs and feed (FSI VGNKI)has a register code "45G37/35-K".

Dry cultural virusvaktsinu against the plague of small ruminants, including vaccinated cultural material derived from an attenuated strain of the virus plague of small ruminants and protective environment as vaccinated cultural material vaccinated vaccine contains cultural material attenuated strain "45G37/35-K titer infectious activity of 5.0-6.0 lg TCD50/cm3and protective environment when the content of component 1:1. As a protective environment it contains medium of the following composition, wt.%: enzymatic peptone 9,8-10,2; lactose 1,8-2,2; distilled water - the rest.

The authors have developed requirements for dry culture virusvaktsinu against the plague of small ruminants, which include the following features: the titer of vaccine virus in the dry preparation is not less than 4.5 lg TCD50/cm3; Pref who ate the dose of vaccine not less than 1000 TCD50duration of immunity is at least 12 months; the shelf life of the vaccine at a temperature of 4±4°C and -40±1°and below 12 and 24 months, respectively; moisture 1-4%; in ampoules (vials) vaccine should be vacuum.

Examples of specific performance information for the manufacture of 2 experienced a series of VirusWall and their physico-chemical and biologic characteristics.

Example 1. Manufacturer VirusWall

For the preparation of two series of VirusWall used vaccinated raw materials obtained in the stationary primary monolayer cultures of kidney cells lamb-based strain 45G37/35-K". The cell culture is grown in a nutrient medium Needle MEM with 10% serum of cattle. After 72 hours mattresses cell culture (10 mattresses on each series of the vaccine) infect with a virus in a dose of 0.01 TCD50/CL and cultured for 7 days before the appearance of the characteristic cytopathogenic actions. After 3 days of cultivation are replaced supporting medium. The activity of the obtained culture of the virus series 1 is 5.7 lg TCD50/cm3series 2-5,5 lg TCD50/cm3.

Each series vaccinated cultural material (1000 ml) are combined with the same amount (1000 ml) protective environment, containing (wt.%): enzymatic peptone - 10; lactose - 2;distilled water - the rest of it.

Prepared process liquid are thoroughly mixed and filled into ampoules of 1 cm3. Drying vaccines hold the dye-sublimation apparatus TG-50, pre-freezing the mixture to -50°C. the drying Time of the vaccine series 1 and 2 is 34 and 37 hours, respectively, ampoules of vaccine is subjected to vacuum processing. Residual moisture in the vaccine series No. 1 and No. 2 was 3.0 and 3.2%, respectively. The growth of bacterial and fungal microflora in the vaccine was not detected.

Example 2. Control of biological indicators vaccines.

Obtained series VirusWall study on the following parameters: biological activity, safety and immunogenic activity.

Biological activity

Titration of VirusWall performed in monolayer in vitro culture of kidney cells saiga in 3 replications according to the standard technique. Activity VirusWall series No. 1 was 5.25 TCD50/cm3series No. 2-5,0 lg TCD50/cm3.

Harmlessness

The harmlessness of each series of VirusWall study 2 lambs three months of age, which is injected subcutaneously with inner thigh undiluted vaccine in a volume of 1.0 cm3. All animals remained clinically healthy during the 21 days of observation.

Immunogenic activity

Immunogenic activity of the vaccine determine elaut on sheep and rabbits (3 heads on each series) in the level of accumulation of VN antibodies in 14 days after vaccination and control of infection of sheep. The grafted venusvalley at a dose of 1000 TCD50sheep did not observe any increase body temperature and symptoms of the disease, i.e. the strain was not reactive. In these terms the VN titer antibodies in the blood serum of the animals was 1:8-1:16.

Vaccinated sheep't get sick after infection with virulent virus at a dose of 1000 EID50whereas control animals (2 heads) are sick of the plague of small ruminants with characteristic clinical signs of disease in 5-10 days after infection.

Example 3. The stability studies of physico-chemical properties and biological activity of the vaccine when stored.

The persistence of dry VirusWall series No. 1 and No. 2 study within 12 and 24 months of storage at temperatures of 4±4°C and -40±1°s, respectively. After the specified time, the vaccine has retained its original activity, which for lots # 1 and # 2 was 5.25 lg TCD50/cm3and 5.0 lg TCD50/cm3respectively.

Residual humidity remained at the original level in the vaccine series No. 1 - 3,0%, series No. 2 (3.2%), the ampoule was kept vacuum.

Thus, the immuno-biological and physical-chemical parameters, subjects series VirusWall against the plague of small ruminants was developed consistent with the requirements.

Dry cultural virusvaktsinu against the plague of small ruminants with a positive result the m was the interdepartmental Commission trials (FGI VGNKI) and generally recognized as safe, highly immunogenic and stable during storage of the drug.

Sources of information

1. A. Abegunde, Ada F.D. // Bull Anim. Hith. Prod. In Africa, 1977, Vol 25, 3.

2. Berhe G. et al. // The Journal of Virology, 2003, Vol.77, 2.

3. Burdin P. // Rev. Elev. Med. Vet. Paes. Trop, 1973, Vol.26, 3.

4. Diallo. A. // Dev Biol (Basel), 2003,114:113-9.

5. Diallo A. et al. // Rev. Elev. Med. Vet. Pays. Trop, 1989, Vol.42.

6. Gibbs, E. P. J. et al. Intervirology, 1979, 11.

7. M.H.V. van Regenmortel et al. // Academic Press, 2000, San Diego.

8. Sarkar J. et al. // Vaccine, 2003, Dec 1;21(32).

9. Wosu L.O.I I Studies Res. Vet. Med., 1994, Vol.2

10. Manual of standards for diagnostic tests and vaccines: list A and In discases of mammals, birds and bees. Office International des Epizooties (OIE) world organisation for Animal health. 2000. P. 114-122.

1. Dry cultural virusvaktsinu against the plague of small ruminants, including vaccinated cultural material derived from an attenuated strain of the virus plague of small ruminants and protective environment, characterized in that as vaccinated cultural material vaccinated vaccine contains cultural material attenuated strain "45G37/35-K" with the titer of infectious activity of 5.0-6.0 lg TCD50/cm3and protective environment when the content of component 1:1.

2. Dry cultural virusvaktsinu according to claim 1, characterized in that it contains a protective medium of the following composition, wt.%:

Enzymatic peptone9,8-10,2
Lactose1,8-2,2
Distilled waterrest



 

Same patents:

FIELD: veterinary, in particular agents for prophylaxis and treatment of viral avian influenza.

SUBSTANCE: invention relates to application of birch bark extract as agent for prophylaxis and treatment of viral avian influenza.

EFFECT: antiviral agent of increased effectiveness.

7 tbl

FIELD: organic chemistry, medicine, virology.

SUBSTANCE: invention relates to novel 2-cycloalkylimino-5-(4-nitrophenyl)-1,3,4-thiadiazines of the general formula (I): wherein the group represents: piperidino-, pyrrolidino-, methylpiperazino-, hexamethyleneimino-group that possess the biological activity against smallpox virus. Invention provides preparing novel biological active compounds possessing an antiviral effect, in particular, against smallpox virus.

EFFECT: valuable biological and medicinal properties of compounds.

1 cl, 1 tbl, 4 ex

FIELD: medicine, in particular surgery, oncology.

SUBSTANCE: claimed method includes immunotherapy, namely on day before operation reaferonum-EC-lipint in dose of 1000-15000 U/kg is perorally administrated to patient. Then in postoperative period blood sampling, extracorporal incubation of leucocytes with imunofan, and intravenous drop administration are carried out. Further for 5 days after operation reaferonum-EC-lipint is perorally administrated to patient dose of 1000-15000 U/kg one time per day. Method of present invention may be used in treatment of patients after radiotherapy in postoperative period. Furthermore method makes it possible to decrease of therapy time by 1.6 times, to reduce total accident number by 2.3 times and decrease of mortality by 2 times.

EFFECT: improved method for rectal cancer treatment.

3 ex, 1 tbl

FIELD: medicine, in particular agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza.

SUBSTANCE: claimed agent contains physiological saline for intravenous administration, comprising hydrogen peroxide, 0.2 % riboxine solution and decoction of liquorice roots in specific ratio.

EFFECT: non-toxic and effective agent for treatment of abovementioned diseases.

7 ex

FIELD: medicine, biotechnology, healthy medical and veterinary preparations.

SUBSTANCE: claimed method includes exposing of aqueous isotonic solution of sugar-containing raw materials such as mixture of glucose and fructose in mass ratio of 1:1 with gamma-irradiation in absorbed dose of 25-40 kGy.

EFFECT: agent of standard composition with high antiviral and hepatoprotective action.

2 tbl, 2 ex

FIELD: medicine, neurology, virology.

SUBSTANCE: invention relates to treatment of neurological diseases caused by herpes virus, such as Bell's paralysis, Hunt's disease, herpetic encephalitis accompanying with damage of cerebral nerves. Invention involves using 1,4-dihydropyridine blockers of calcium channels, such as felodipine, nifedipine, nimodipine, nisodipine being taken preferably in combination with herpes virus antagonist. Invention provides repairing damaged cerebral nerves by topical expanding arteriols and recovery of local microcirculation based on specific competitive interaction of definite groups of calcium blockers of 1,4-dihydropyridine type with vasoconstrictor endothelin.

EFFECT: enhanced effectiveness of treatment.

47 cl, 2 dwg, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a cycloferon-containing medicinal agent used in prophylaxis and treatment of influenza and acute respiratory diseases, herpetic infection, chronic viral hepatitis B and C and prophylaxis of oncological diseases. Agent comprises a physiological solution in the following ratio of components: 10-29 - 10-2 mg of cycloferon in 1 ml of physiological solution. Also, invention relates to a method for preparing this medicinal agent. Proposed medicinal agent enhances antiviral and antitumor activity of natural killers by 1.8-fold, not less.

EFFECT: improved preparing and using method, valuable medicinal properties of agent.

7 cl, 1 dwg, 19 ex

FIELD: veterinary science.

SUBSTANCE: it is necessary to inject birch bark extract for the animal at the dosage of 20 or 40 mg/kg body weight. The present innovation enables to increase leukocytic immunocompetence that, in its turn, prevents viral proliferation and disease relapses.

EFFECT: higher efficiency of therapy.

2 cl, 1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: the suggested strain refers to DNA-containing Adenoviridae type being of cubic type of symmetry, has no supercapsid membrane, virions sizes - 70-80 nm, shape - icosahedral. Moreover, it is resistant to the temperature of 56°C for 30 min, not less, and to the action of both ether and chloroform. It is inactivated with formalin, theotropin, dimer ethylenimine. The strain is cultivated in hepatic cell culture of hen's embryos, about 72-96 h after infection it causes characteristic foci of granulation (cells' rounding), the formation of separate rounded cells and foci of cell degeneration. Viral titer is within 105.5 TCD50/ml. The strain enables to reproduce different forms of the disease mentioned for experimental investigations, it is highly useful for manufacturing certain diagnostic kits and vaccines, moreover, being of high antigenic and immunogenic activity.

EFFECT: higher efficiency.

2 ex

Antiviral substance // 2276988

FIELD: medicine, virology, pharmacology.

SUBSTANCE: invention relates to an antiviral substance based on hemolymph of insects of subclass Pterigota. This substance is prepared by activation of immune system of insects, collection of hemolymph and the following treatment of prepared hemolymph by centrifugation, chromatography of supernatant, elution of hydrophobic components sobbed on column. Prepared eluate comprises a mixture of hydrophobic components possessing with an antiviral activity. Invention provides the direct antiviral effect and enhances resistance of body cells to viral infection by virus disruption or blocking its replication, or by other method.

EFFECT: improved preparing method, valuable antiviral properties of substance.

41 cl, 1 tbl, 1 dwg, 1 ex

FIELD: biotechnology, vaccines.

SUBSTANCE: method involves preparing industrial strain, smallpox scrape off and virus-containing liquid. Virus-containing liquid is inactivated by gamma-radiation Co60. Integral (total) dose of irradiation is 1.75 x 106 R at the parent specific activity of virus-containing liquid from 1 x 109 to 1.9 x 109 OOE/ml and 1.9 x 106 R at the parent specific activity of virus-containing liquid from 2 x109 to 5 x 10 OOE/ml. The content of total protein is brought about to the concentration 100 mcg/ml and drying stabilizing agents are added. Vaccine elicits high immunogenicity, suitable in applying and absence of toxicity.

EFFECT: improved preparing method, improved and valuable properties of vaccine.

3 cl, 6 ex

FIELD: veterinary science.

SUBSTANCE: the present method deals with applying biological preparations for vaccinating farm animals and could be applied for protecting female goats against variola. The present innovation deals with a single subcutaneous injection of dry culture virus vaccine against ovine variola for female goats at the quantity of two vaccination dosages. The innovation enables to accelerate the development of tense immunity to variola virus in goats along the absence of post-vaccinal complications and prolong immunity by 8 mo, not less.

EFFECT: higher efficiency of prophylaxis.

3 ex, 1 tbl

The invention relates to the field of veterinary medicine

The invention relates to the field of veterinary Virology, in particular to a method for the diagnosis of sheep pox and goat

The invention relates to the field of veterinary medicine, in particular to the use of biological agents for simultaneous specific prophylaxis of anthrax and small pox in sheep

The invention relates to veterinary Virology and biotechnology, and in particular to methods of obtaining living culture vaccine against sheep pox, and can be used at the enterprises of biological industry

The invention relates to biotechnology and can be used to produce vaccines

FIELD: veterinary science.

SUBSTANCE: the present method deals with applying biological preparations for vaccinating farm animals and could be applied for protecting female goats against variola. The present innovation deals with a single subcutaneous injection of dry culture virus vaccine against ovine variola for female goats at the quantity of two vaccination dosages. The innovation enables to accelerate the development of tense immunity to variola virus in goats along the absence of post-vaccinal complications and prolong immunity by 8 mo, not less.

EFFECT: higher efficiency of prophylaxis.

3 ex, 1 tbl

Up!